Loncastuximab tesirine in previously treated WM

Recruiting
Written By Sustainable Digital

First trial using an ADC (antibody-drug conjugate) for WM in the world

Sites: Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Mayo Clinic, Fred Hutchinson Cancer Center

Accrual status: 21 of 21 patients

Highlight: Presentations at IWWM 13 and at ASH 2025

Sustainable Digital

Digital Communication services, including website design, search engine optimization, social media, and content creation for nonprofit organizations, consultants, and creative entrepreneurs.

http://www.sustainabledigital.com
Next

Zanubrutinib, Bendamustine, and Rituximab (ZEBRA) in previously untreated WM